Research programme: therapeutic monoclonal antibodies - Takeda/XOMA
Latest Information Update: 04 Nov 2017
At a glance
- Originator Takeda; XOMA
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in Japan (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in Japan (Parenteral)